

Curriculum Vitae

Dr Mario Polywka

Academic degree: DPhil in mechanistic organometallic chemistry, University of Oxford

Occupation: Independent consultant

Place of residence: Oxfordshire/UK

Personal data

Year of birth: 1963

Nationality: British

Member of the Supervisory Board of Evotec SE

First appointment to the Supervisory Board of Evotec SE: 19 June 2019

End of term: End of Annual General Meeting 2024

Education

1988 – 1989 University of Oxford

PostDoc

1985 – 1988 University of Oxford

Conferral of a doctorate (DPhil in mechanistic organometallic chemistry)

1981 – 1985 University of Oxford

Bachelor of Arts

Professional career

Since June 2019 Member of the Supervisory Board of Evotec SE

Since Jan 2019 Independent consultant

2007 – 2018 Evotec AG

Member of Management Board and Chief Operating Officer



2004 – 2006	Evotec AG Executive Vice President
2002 – 2004	Consultant
1991 – 2002	Evotec OAI AG Various positions, most recently Chief Operating Officer

Appointments to other statutory supervisory boards and comparable national and international supervisory bodies of commercial enterprises

Blacksmith Medicines, Inc., USA	Non-executive Director
C4X Discovery Holdings PLC, UK	Non-executive Director
Exscientia plc, UK	Non-executive Director
Orbit Discovery Limited, UK	Non-executive Director

Other significant activities besides the Supervisory Board mandate

n/a

Relevant knowledge, skills and experience

Dr Mario Polywka (born in 1963, British citizen) was appointed Member of the Supervisory Board on 19 June 2019 for a term of five years. His current term will expire at the end of the Annual General Meeting held in the year 2024.

Dr Polywka retired from the Management Board of Evotec AG effective 31 December 2018. Until then, he served as member of the Management Board and Chief Operating Officer of Evotec AG since 28 November 2007.

In 1991, he was a founding chemist of Oxford Asymmetry International plc (OAI), became Director of Chemistry in 1993 and a Board Director in 1996. In 1999, Dr Polywka was appointed Chief Operating Officer and in 2000 Chief Executive Officer of OAI. Following the merger of EVOTEC BioSystems AG with OAI in 2000, he was Chief Operating Officer until 2002. Between 2002 and 2004, Dr Polywka ran a number of spin-out companies from Oxford and Southampton Universities.

Dr Polywka received his Bachelor's degree from Hertford College, Oxford University and his Doctorate from the University of Oxford in mechanistic organometallic chemistry with Professor Steve Davies and continued at Oxford with post-doctoral studies on the biosynthesis of Penicillin with Professor Sir Jack Baldwin. He held a number of college teaching posts at Oxford University between 1988 and 1994.

Dr Polywka is a Fellow of the Royal Society of Chemistry and has a number of publications and patents mainly in the field of asymmetric synthesis.

In May 2017, Dr Mario Polywka became a member of the Board of Directors of Forge Therapeutics, Inc. and in September 2017, Dr Mario Polywka also joined the Board of Directors of Exscientia Ltd. In September 2019, Dr Polywka was appointed Non-Executive Director at the UK biotech company Orbit



Discovery, and has accepted a position as Senior Advisor with MCF Corporate Finance. He has served as Non-Executive Director at UK based company C4X Discovery Holdings PLC since December 2021.

Personal or business relationships in accordance with items C.6 to C.12 of the German Corporate Governance Code

Dr Mario Polywka, who served as COO of Evotec until 31 December 2018 and who was elected to the Supervisory Board on the recommendations of a group of shareholders who together hold more than 25% of the total number of voting rights in the Company, is regarded as not independent.

Latest update: December 2023